Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

Dexcom was issued with an FDA warning letter after issues with “manufacturing processes and quality management systems.” ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

In other words, for those looking for "forever stocks," it's not a bad idea to look in this sector. And even with a modest sum -- such as $200 -- we can find excellent healthcare corporations to ...

DexCom's growth is slowing with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% ...

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

Statement via Dexcom’s website “Hopefully it is just a short-term, not a long-term thing that we will have to do because we see that if they have that CGM on, it’s more reliable,” said Dr. Bruner-Hill ...

DexCom’s strong revenue growth projection for 2025, driven by continued market expansion, broader access wins and advancements in its CGM technology, looks promising. Key plans include the ...

DexCom (NasdaqGS:DXCM) recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact ...